Seeking Alpha

Idenix initiates Phase 2 HCV trial, files patent infringement suits against Gilead

  • Idenix Pharmaceuticals (IDIX) starts patient enrollment in HELIX-2 — that's the DAA HCV combo comprising samatasvir and the JNJ co-developed protease inhibitor and polymerase inhibitor simeprevir and TMC647055.
  • The Phase 2 study will evaluate efficacy, safety and tolerability of the combo in treatment-naïve or relapsed (after interferon and ribavirin) GT1 HCV patients. (PR)
  • In other company news, IDIX has filed two patent infringement lawsuits against Gilead (GILD) tied to methods of treating the HCV using 2'-methyl nucleosides.
  • Here's IDIX: "[The company] is seeking a declaration that GILD's imminent distribution, importation, use, sale or offer to sell drugs containing sofosbuvir, a 2'-methyl nucleoside compound, infringes IDIX's patents." (PR)
Comments (2)
  • rnn
    , contributor
    Comments (310) | Send Message
     
    Its selling off on the positive article/news.
    2 Dec 2013, 01:13 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (733) | Send Message
     
    a patent suit.. oh boy. Here we go. Patents are almost worthless in today's age
    2 Dec 2013, 03:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs